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ABSTRACT 
Can Minocycline Reduce Cytokine-Induced Bone Resorption After SCI? (May 2016) 
Sammy Gong 
Department of Neuroscience 
Texas A&M University 
Research Advisor: Dr. Michelle Hook 
Department of Neuroscience and Experimental Therapeutics 
Spinal contusion injuries are characterized by an increased excitation of the immune system that 
results in inflammation and heightened expression levels of pro-inflammatory cytokines in the 
central nervous system (CNS) (Donnelly et al. 2008). These inflammatory cytokines impair bone 
homeostasis to favor bone resorption over the secretion of bone matrix, thus contributing to an 
overall decline in bone mineral density (BMD) (Perez-Castrillon et al. 2000, Schett 2011). 
Maintenance of bone integrity following spinal cord injury (SCI) is critical because low BMD 
compromises locomotor and sensory recovery, and is a predictor of bone pain, future fractures, 
and osteoporosis. We proposed that minocycline, an FDA-approved anti-inflammatory drug 
(Kobayashi et al. 2013), may protect against the BMD deterioration routinely observed after SCI. 
To test this, male Sprague Dawley rats were given a moderate spinal contusion injury and then 
treated with 0 or 0.33 mg/kg/ml of minocycline from days 1-14 following injury. Recovery of 
function was assessed for 28 days post injury. At the end of the experiment, bone samples 
werecollected to assess BMD and changes in amount of mineralization. Administration of 
minocycline significantly enhanced active bone mineralization and overall new bone formation 
rates in a rodent SCI model compared to vehicle-treated SCI controls. A more comprehensive 
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understanding of the effects of different therapeutic strategies for alleviating post-injury bone 
loss is important for the development of effective treatment strategies to improve long-term 
rehabilitation following SCI. 
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CHAPTER I 
INTRODUCTION 
The structure of bone is a unique composite of living cells embedded in a three-dimensional 
mineralized structure of inorganic salts and organic matrix. The inorganic salt component of 
bone primarily consists of phosphate and calcium ions, but also includes substantial amounts of 
sodium, potassium, magnesium, carbonate, fluorite, zinc, barium, strontium, and other minerals. 
The organic matrix of bone consists of collagenous proteins and non-collagenous proteins such 
as bone morphogenetic proteins (BMPs), osteocalcin, fibronectin, osteonectin, and growth 
factors (Boskey et al. 2002). The extracellular matrix of bone is a complex and organized 
framework that gives it mechanical support and serves as a substrate for bone homeostasis. Like 
most dynamic tissues, bone has the ability to adapt to its environment and it does so by changing 
its internal structure through the resorption of old bone and the laying down of new bone matrix, 
a process collectively called bone remodeling. Remodeling is a fundamental characteristic of 
bone that helps it manage the delicate equilibrium between mineral resorption and deposition to 
ensure skeletal integrity. When the balance between bone formation and resorption is lost in 
favor of the latter, the consequence is bone loss and a number of bone diseases. To illustrate the 
effects of a disruption in the equilibrium between formation and resorption in bone homeostasis, 
the mechanisms behind periodontitis and osteopetrosis may be considered. In periodontitis, a 
bacterial infection induces the proliferation of inflammatory cells that produce cytokines, or 
chemical mediators, that stimulate the accumulation of osteoclasts. This abundance of osteoclasts 
results in abnormally increased bone resorption in the alveolar bone to produce loosening of 
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teeth. In contrast, those suffering with osteopetrosis have mutated osteoclasts with diminished 
resorptive functions. The consequence of decreased bone resorption from these mutated 
osteoclasts is the excessive accumulation of bone mass which, like reduced BMD, also results in 
an increased likelihood of fractures (Longhini et al. 2014, Sobacchi et al. 2013). Because the 
remodeling process is so intimately tied to the pathophysiology of osteoporotic and osteopetrotic 
conditions, understanding how remodeling is regulated is key to the effective prevention of bone-
related afflictions. The coordinated activities of two types of cells determine the outcome of bone 
metabolism: osteoblasts that secrete matrix for bone formation and osteoclasts that absorb bone 
tissue during growth and healing. Osteoblasts are of mesenchymal origin while osteoclasts are 
hematopoietic in origin and are derived from the monocyte phagocytic system of organisms 
(Gilbert 2000). 
Processes of bone remodeling 
Two processes result in the formation of healthy bone tissue: intramembranous ossification and 
endochondral ossification. The former occurs when bone is directly laid down into primitive 
connective tissue called mesenchyme while the latter occurs when cartilage is utilized as a 
precursor to the bone. In intramembranous ossification, osteoblasts secrete a collagen-
proteoglycan matrix that binds calcium salts to produce calcified bone. Osteoblasts are typically 
kept separate from the site of calcification when collagen-proteoglycan matrix is being bound to 
osteoid or pre-bone matrix, but periodically osteoblasts may become trapped in the calcified 
matrix and become osteocytes, or bone cells. As calcification progresses, bone spicules emit 
from the region where ossification began and the entire locale of spicules radiation eventually 
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becomes encompassed by compact mesenchymal cells to form the periosteum, a layer of 
vascular connective tissue that envelopes the bone. Cells on the internal surface of the 
periosteum differentiate into osteoblasts and continue to deposit osteoid matrix parallel to the 
existing aforementioned spicules to form the many layers of bone. The mechanism behind 
intramembranous ossification involves bone morphogenetic proteins (BMPs) and a transcription 
factor, CBFA1, that activates the genes for a multitude of bone-specific extracellular matrix 
proteins. Mesenchymal cells aggregate to form the cartilage precursor to be replaced with bone 
in endochondral ossification, which can be organized into five phases. During the first phase, a 
portion of mesenchymal cells are selected to differentiate into cartilage cells, which is facilitated 
by paracrine factors that induce nearby mesodermal cells to express transcription factors, Pax1 
and Scleraxis, that activate cartilage-specific genes and induce the formation of cartilaginous 
precursors to bone. In the course of the second phase, the selected mesenchymal cells condense 
and differentiate into chondrocytes, or cartilage cells. In the third phase, the chondrocytes divide 
rapidly and secrete a cartilage-specific extracellular matrix that becomes the framework of the 
premature bone. In the fourth phase, the chondrocytes cease division and become enlarged, or 
hypertrophic, chondrocytes that have the ability to alter the cartilaginous matrix with the addition 
of collagen X and excess fibronectin. This alteration allows the cartilage to be mineralized with 
calcium carbonate. Hypertrophic chondrocytes also release small membrane-bound vesicles 
containing enzymes active in the generation of calcium and initiation of mineralization into the 
cartilage-specific extracellular matrix. The fifth and final phase of endochondral ossification 
entails the apoptosis of the hypertrophic chondrocytes and the annexation of the completed 
cartilage substructure with blood vessels. The space left behind by the enlarged chondrocytes 
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become bone marrow and cells in its vicinity differentiate into osteoblasts that proceed to 
synthesize bone matrix on the surface of the cartilage framework. The cartilage precursor is 
simultaneously degraded as osteoblasts work to lay down new bone matrix in its place, thus 
endochondral ossification is characterized by the use of cartilage as a blueprint for the final bone 
product. This replacement of cartilage cells by bone cells is contingent upon the mineralization 
of the cartilage-specific extracellular matrix with calcium carbonate and the hypertrophy of 
chondrocytes (Gilbert 2000). 
While synthesis of bone is done by osteoblasts, the destruction of bone tissue is the work of 
osteoclasts, which are terminally differentiated multinucleated cells that access bone through the 
blood vessels previously described in the endochondral process of bone formation (Gilbert 
2000). Aside from osteoclasts, blood vessels also import the blood-forming cells of bone marrow. 
To elaborate on its origins, osteoclasts are thought to be derived from the same progenitor cells 
as macrophage blood cells and have the ability to dissolve both inorganic and protein 
constituents of bone matrix (Florencio-Silva et al. 2015). The cell membranes of osteoclasts are 
endowed with energetic ion channels that pump protons into their extracellular space to cause a 
drastic lowering of pH within the cells’ own microenvironment. Further, osteoclasts bear many 
vesicles and vacuoles containing lysosomes filled with acid phosphatase and collagenase that 
work together to dissolve neighboring bone mineral. Numerous cellular processes radiate into 
bone matrix from osteoclasts to pump hydrogen ions out and acidify tissue in order to effectively 
solubilize it (Kornak et al. 2001, Graves et al. 2008). Due to its catabolic nature, osteoclast 
numbers must be rigorously regulated to ensure coherence of bone. At a site of active bone 
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resorption, the osteoclast forms a specialized extensively folded cell membrane that facilitates 
bone removal by increasing the cell surface for the secretion of proteins that catabolize bone and 
for the uptake of resorption contents (Lin et al. 2015). During remodeling, osteoclasts divide to 
produce four types of osteoclastic membrane domains: the sealing zone, the ruffled border, the 
basolateral secretory domain, and the functional secretory domains. The former two are kept in 
contact with the bone matrix while the latter two are not. The ruffled border is fabricated by 
microvilli isolated from adjoining tissue by the sealing zone, which is an area deprived of 
organelles near the edges of the osteoclast adjacent to the bone matrix (Gilbert 2000). The ruffled 
border contains a hydrogen ion ATPase that helps to acidify resorption lacunae to enable the 
dissolution of bone mineral. Because the ruffled border is formed due to acute trafficking of 
lysosomal and endosomal components, its maintenance is essential for osteoclast activity. The 
products of this degradation of extracellular matrix are eventually endocytosed across the ruffled 
border and transcytosed to the functional secretory domain located at the plasma membrane. 
There is evidence that osteoclasts exhibit several other functions in addition to bone mineral 
dissolution. Some findings have shown that osteoclasts have the ability to release clastokines, or 
osteoclast-derived coupling factors, that regulate osteoblast activity during bone remodeling 
(Schell et al. 2006). Here, coupling refers to the collaborative processes of bone formation and 
bone resorption. Other findings indicate that osteoclasts may play a role in the regulation of the 
hematopoietic stem cell niche (Mansour et al. 2012). Together, these findings suggest that 
osteoclasts are a source of cytokines that influence the activity of other cells. 
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Role of cytokines in bone remodeling 
The activity of both osteoblasts and osteoclasts are regulated by numerous factors, one of them 
being cytokines. Cytokines are regulatory factors secreted by cells to manage host immune 
responses to infection, trauma, and inflammation. Cytokines can worsen conditions (pro-
inflammatory) or promote healing (anti-inflammatory), but are often detrimental to the host 
during incidents of overwhelming trauma. Interleukin (IL-1) and tumor necrosis factor (TNF) are 
examples of pro-inflammatory cytokines that can result in fever, inflammation, and necrotic 
tissue. There is emerging evidence to suggest that cytokines determine whether mesenchymal 
cells differentiate into osteoclasts or other bone-related cell lineages. Specifically, studies have 
shown that pro-inflammatory cytokines have the potential to stimulate osteoclast formation, 
consequently increasing bone resorption (Weitzmann 2013). In osteoclastogenesis, the 
stimulation of mononuclear osteoclast progenitors by macrophage colony-stimulating factor (M-
CSF) and receptor activator of nuclear factor-kB ligand (RANKL) is crucial. Both M-CSF and 
RANKL serve as inducers of osteoclast differentiation and promotors of mononuclear progenitor 
fusion to mature, multinucleated osteoclasts. M-CSF binds to its receptor, cFMS, in osteoclast 
precursors to stimulate their proliferation and inhibit their apoptosis. When RANKL binds to its 
receptor, RANK, in osteoclast precursors, osteoclast proliferation is likewise stimulated. 
Osteoprotegerin (OPG) is the third component of the RANKL/RANK mechanism that serves as 
a decoy receptor for RANKL. OPG binds to RANKL and prevents it from associating with its 
customary receptor, RANK, to inhibit osteoclast differentiation. Numerous other inflammatory 
cytokines similar to RANKL are able to drive osteoclastogenesis and regulate bone resorptive 
activities (Weitzmann 2013). 
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SCI, cytokines, and bone remodeling 
Concentrations of TNF, a cell death-inducing cytokine, increases after SCI but intraperitoneal 
injections of the anti-inflammatory cytokine interleukin-10 (IL-10) half an hour post-injury were 
able to mitigate the production of TNF-a by macrophages. Additionally, the same IL-10 
injections also improved recovery of hindlimb function as measured by the BBB locomotor 
rating scale. Not only do the outcomes of this study insinuate that early attenuation of 
inflammation may be beneficial for neuroprotection, but they also insinuate a relationship 
concerning the regulation of pro-inflammatory cytokines with anti-inflammatory factors, TNF-a 
and IL-10 in this case, respectively. It seems that a reduction in inflammation is sufficient for 
substantial improvement in locomotor function post-SCI. The question now is whether this 
minimization of inflammation by means of anti-inflammatory factors is also sufficient for 
improvement in bone preservation and recovery, seeing that recovery of locomotor function is 
often associated with a degree of bone integrity. This study provides significant implications for 
conditions characterized by inflammation near bone, such as SCI, because it suggests a direct 
relationship between inflammation and skeletal integrity. Following injury to the spinal cord, 
inflammatory reactions take place that result in increased pro-inflammatory cytokine levels in 
serum, the clear liquid partitioned from blood coagulate (Brewer et al. 1999). This inflammation 
may impact bone formation. Indeed, studies examining the effects of SCI on bone mineral 
density (BMD), a measure reflecting the strength of bones by calcium content, have shown 
decreased mineral values in measured regions of the lumbar spine and hip compared to that of 
controls. Specifically, BMD values of the hip decreased as the duration of SCI increased and 
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levels of calcium in 24-hour urine samples were found to be significantly higher in the patient 
group than the control group (Kurtulus et al. 2006). SCI-induced bone loss portrays serious 
osteoporosis with no effective treatment. 
In addition to SCI per se, medications that are routinely used to treat pain, including opiates such 
as morphine, may affect skeletal integrity. Morphine significantly increases levels of pro-
inflammatory cytokines, specifically IL-IB, after SCI (Hook et al. 2011). Studies have also 
shown that 50% of a cohort receiving intrathecal opioid doses for SCI-related pain demonstrated 
osteopenia, with more than 20% of the cases diagnosed as osteoporosis, the more severe form of 
bone loss (Duarte et al. 2013). Opioids are thought to impede bone synthesis by binding to mu 
receptors located on osteoblasts and directly inhibiting their activity. Osteoblast inhibition leads 
to decreased synthesis of bone, and subsequently decreased BMD. Osteocalcin, a non-
collagenous protein of bone, can be utilized as a biomarker for osteoblast activity and chronic 
opioids users have been shown to exhibit decreased osteocalcin concentrations (Shadid et al. 
2013). In addition to their inhibitory effects on osteoblasts, opioid use can also engender 
osteoporosis by suppressing the production of certain hormones like testosterone, which leads to 
a condition called hypogonadism, which can weaken bones in both men and women (Brennan 
2013, Smith et al. 2012). Conventional analgesics, including opioids, are among the most 
effective treatments for pain. Alarmingly, these studies suggest that opioids significantly 
undermine the long-term recovery of bone mineral and counter-intuitively increase the 
expression of symptoms of neuropathic pain in a rodent model of SCI (Hook et al. 2011). This 
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calls for improved therapies for bone-related traumas that accounts not only for the onset of 
neuropathic pain, but for prevention of bone loss as well.  
Investigating the relationship between bone remodeling and inflammation after SCI 
The inflammatory response exhibited by the immune system is a result of tissue injury; damaged 
cells release chemicals that promote swelling. The role of inflammation in the midst of SCI is 
evidently beneficial for neural recovery, but it also bears deleterious effects. There is evidence 
that immediate inflammatory responses in the CNS are specialized to curb possible infection and 
clean up cellular debris rather than to aid in the post-trauma repair processes (Zhang 2009). 
Injury activates the transformation of quiescent microglia into macrophage-like cells that 
produce pro-inflammatory cytokines. These pro-inflammatory cytokines and other analogous 
cellular factors spark a response cascade that recruits additional quiescent microglia. Further, the 
presence of cellular debris stimulates dormant astrocytes to express cytokines, glial fibrillary 
acidic protein (GFAP) and various other factors that may contribute to prolonged inflammation 
(Watkins 2002). Since molecules typically involved in immune function are present at the site of 
SCI, this is an ideal research model in which to investigate possible pharmacological 
interventions that may counter the deleterious effects of molecular immune responses on bone 
density. 
Minocycline is a broad-spectrum tetracycline antibiotic, meaning that it is a general-use bacterial 
inhibitor. Of the tetracycline-class antibiotics, minocycline is the most lipid-soluble and is able to 
penetrate into the brain with relative ease. In previous rodent SCI models, intravenous 
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administration of minocycline improved neurological outcomes, reduced neuronal apoptosis, 
decreased microglial activation, and reduced inflammation (Wells 2003). Minocycline is 
currently in phase III clinical trials, meaning it is being given to large groups of people to 
confirm its effectiveness, monitor its side effects, compare it to commonly used treatments, and 
collect information that will enable the pharmaceutical to be safely utilized (https://
clinicaltrials.gov/ct2/show/NCT01828203). Due to the link between pro-inflammatory cytokines 
and bone disease, minocycline, an antibiotic glial inhibitor that has been shown to reduce 
inflammation in vivo (Kobayashi 2013), may be able to counter the deleterious effects of post-
trauma immune responses on bone homeostasis and improve mineral retention in a rodent model 
of spinal cord injury. The present experiment will test this hypothesis and will further 
understanding of the correlation between bone integrity and inflammation. Moreover, this study 
will inform clinical practice by evaluating therapeutic strategies that may reduce osteoporotic 
comorbidity in individuals with SCI and improve long-term recovery. Low BMD and bone 
disease are serious afflictions that may hinder the holistic recovery of SCI patients not just 
physically, but mentally as well due to excessive amounts of neuropathic pain (Nicholson et al. 
2004). Further, bone retention is also crucial for other injuries in proximity to bone aside from 
SCI because they tend to bear similar models of recovery with analogous issues. Consequently, 
there should be an urgency to alleviate these sufferings not only for the benefit of the hundreds of 
thousands that experience SCI every year but for those experiencing other bone-related injuries 
such as  periodontitis, arthritis, and various others as well.  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CHAPTER II 
METHODS 
Twelve singly-housed male Sprague-Dawley rats were given a moderate spinal contusion injury 
(IH impactor, 150 kdynes with 1 second dwell time) at the T12 vertebral level using the Infinite 
Horizon spinal cord impactor (PSI, Fairfax Station, VA). Subjects were anesthetized with 
isoflurane (5%, gas), and after stable anesthesia was achieved the concentration of isoflurane was 
lowered to 2-3%. Twenty-four hours after injury, and after balancing locomotor function (BBB 
scores) across groups, the SCI subjects were randomly assigned to one of two treatment 
conditions: 0 or 0.33 mg/kg/ml minocycline. They were provided with free access to the 
minocycline in their drinking bottles from days 1-14 post-injury. The daily amount of fluid/
minocycline consumed was recorded. To control for the effects of SCI per se on bone loss, 
locomotor recovery and osteological assessments were also conducted with eight intact rats. 
Locomotor recovery assessments 
Recovery was assessed for a 28-day period following SCI. Locomotor recovery was determined 
using the BBB scale (Basso et al. 1995) in an open enclosure (99 cm diameter, 23 cm deep). The 
converted BBB scale (Ferguson et al. 2004) is a 12-point scale that is conventionally used as an 
index of hindlimb functioning after a spinal injury. Using this scale, no movement of the 
hindlimbs (ankle, knee or hip) is designated a score of 0, and intermediate milestones include 
slight movement of one joint (1), extensive movement of all three joints (5), occasional weight 
supported stepping in the absence of coordination (8), and consistent weight supported stepping 
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with consistent FL-HL coordination (12). Baseline motor function was assessed on the day 
following injury and prior to drug treatment. BBB scores were also collected on Days 1-7, 9, 11, 
13, 15, 18, 21, 24, and 28 post injury. Because rodents often freeze when first introduced to a 
new apparatus, subjects were acclimated to the observation fields for 5 min per day for 3 days 
prior to surgery. Each subject was placed in the open field and observed for 4 min. Care was 
taken to ensure that the investigators’ scoring behavior had high intra- and inter-observer 
reliability (all r’s > 0.89) and that they were blind to the subject’s experimental treatment. 
At the end of the 28-day assessment period, subjects received a lethal injection of beuthanasia 
(100 mg/kg) and the injured spinal (1 cm section centered on the lesion) and bone tissue was 
collected and processed to assess changes in bone formation with minocycline treatment. This 
two dose experimental design required twelve rats. Eight additional intact subjects were assessed 
as injury controls. 
Osteological assessments 
Bone analyses were conducted using dynamic cortical histomorphometric methods (Dempster et 
al. 2013) and peripheral quantitative computed tomography (pQCT). Subcutaneous injections of 
calcein, an orange-colored fluorescent dye, were administered on days 21 and 26 post-injury (7 
and 2 days prior to termination) to label mineralizing surfaces for later determination of bone 
formation rates. Un-demineralized, excised left distal tibias were fixed in 4% phosphate-buffered 
formalin for 24 hours, and then serially dehydrated and embedded in methyl-methacrylate. Serial 
cross sections (approximately 100 µm thick) of the bone closest to the mid shaft were made on a 
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diamond wafer IsoMet Low Speed Saw (Buchler, Lake Bluff, IL) starting 1 mm proximal to the 
tibia-fibular junction. Cross sections of each specimen were analyzed at 20x magnification using 
OsteoMeasure Analysis Software version 3.3 (OsteoMetrics, Inc., Atlanta, GA). Mineralizing 
surface to bone surface ratio (MS/BS), mineral apposition rate (MAR), and bone formation rate 
(BFR = MS/BS x MAR), were determined. MAR is the rate at which new bone is deposited in 
the radial direction while BFR is an overall measure of new bone formation calculated by 
multiplying the percentage of surface actively forming new bone with the radial rate of that 
formation.  
Right tibias were similarly preserved in phosphate buffered saline in -35oC. Once thawed, ex-
vivo pQCT scans of the proximal tibia metaphysis (mixed cortical and cancellous bone site) and 
mid-shaft tibia (purely cortical bone site) were completed on a Stratee XCT Research-M device 
(Norland Corp., Fort Atkinson, WI). Metaphysical volumetric BMD was measured at the 
proximal tibia and distal femur from 4 slices located at least 1 mm distal of the growth plate. 
Three contiguous slices were averaged to provide one value for each variable at the proximal 
tibia metaphysis. One mid shaft tibia slice was taken at approximately 50% of the total bone 
length. Scans were completed at 2.5mm/sec scan speed, 100 µm voxel resolution, and 0.5 mm 
slice thickness. Measures obtained from the ex vivo pQCT scans include cortical and total and 
cortical bone mineral content (BMC). The metaphysis is a broad portion of the length of bone 
between the epiphysis and diaphysis; it comprises the growth plate, which is the part of the bone 
that grows during adolescence. Cancellous bone refers to the meshwork of spongy tissue of 
mature bone typically found at the ends of long bones such as the femur. Cortical bone refers to 
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the dense outer surface of bone that forms the protective layer around the internal cavity; it 
constitutes nearly 80% of skeletal mass and is highly resistant to bending and torsion.  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CHAPTER III 
RESULTS 
Locomotor recovery 
Mean BBB scores ranged from 6.81 ± 0.56 for the water group and 6.78 ± 0.71 for the 
minocycline group. A slight increase in locomotor recovery was observed for the minocycline 
group compared to the water group towards the end of recovery, but there were no significant 
differences between the two treatment groups (Figure 1). 
OsteoMeasure 
The mineralizing bone surface to total bone surface ratio (MS/BS), mineral apposition rate 
(MAR), and bone formation rate (BFR/BS) measurements for each SCI treatment group and the 
intact control group were averaged and the standard errors of the means were calculated. The 
control group for these three measures consists of 5 rats instead of 8 due to time-related 
restrictions. Using one-way ANOVAs it was determined that the difference in MAR was not 
significant between the two SCI treatment groups and the intact group (F (1, 11)=1.079, p>0.05), 
but BFR (F (1, 11)=14.540, p<0.0001) and MS (F (1, 11)=21.536, p<0.0001) did differ across the 
groups (Figures 2, 3, and 4, respectively). Duncan’s post-hoc showed that BFR was significantly 
higher in the intact controls, compared to both SCI groups (p<0.05). SCI subjects treated with 
minocycline also had significantly higher BFR than vehicle-treated SCI controls (p<0.05). 
Similarly, MS was significantly higher in the intact subjects, compared to the SCI groups, and 
higher in minocycline-treated SCI subjects than vehicle-treated SCI controls (p<0.05). The BFR 
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and MS was highest for the intact controls, Minocycline-treated SCI, and then vehicle-treated 
SCI groups in descending order. 
Peripheral quantitative computer tomography 
The total bone mineral content (BMC), total bone mineral density (BMD), total bone area, 
cancellous BMC, cancellous BMD, cortical BMC, and cortical BMD for the rats, including the 8 
controls, were assessed using pCQT scanning, averaged for each treatment group, and standard 
errors of the means were calculated. There was a trend for lower total BMD in the minocycline 
group compared to the water group (Figure 5), although the difference was not significant 
(p>0.05). There was also a trend for lower total cortical BMD in the minocycline group (Figure 
6), although the difference was not significant (p>0.05). There were no significant differences in 
the total cancellous BMD across groups (Figure 7).  
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Figures 
Figure 1. Minocyline treatment did not affect recovery of locomotor function. 
Figure 2. No significant differences in MAR as a result of surgery of drug treatment were 
observed. 
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Figure 3. The minocycline group showed significantly higher BFR compared to the water group. 
**p<0.05 
 
Figure 4. The minocycline group showed significantly higher MS compared to the water group. 
**p<0.05 
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Figure 5. There is a trend for lower total BMD in the minocycline group compared to the 
vehicle-treated SCI group, though the difference is not significant. 
Figure 6. There is a trend for lower total cortical BMD in the minocycline group compared to the 
vehicle-treated SCI group, though the difference is not significant. 
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Figure 7. There were no significant differences in total cancellous BMD across surgery of drug 
treatment groups.  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CHAPTER IV 
DISCUSSION 
Minocycline, an anti-inflammatory glial inhibitor, was able to improve osteological outcomes 
after a traumatic spinal cord injury. Surprisingly, however,  rather than increasing bone density in 
the rodent model of SCI, minocyline appeared to induce new bone formation. Thus, our initial 
hypothesis that the tetracycline drug could reduce cytokine-induced bone resorption was not 
supported (Figure 5). Nonetheless, the drug administration group showed higher levels of 
mineralizing surface and overall bone formation compared to the water group. This suggests that 
minocycline may function by increasing osteoblast activity instead of reducing osteoclast 
activity, which was originally hypothesized. The anti-inflammatory properties of minocycline 
were thought to counter the consequences of inflammatory cytokines that served to excite 
osteoclastogenesis, but whether this occurs is not clear with the data provided by this study. 
Post-SCI loss of bone mass is typically attributed to an unbalanced bone homeostasis with 
resorption exceeding bone formation, ultimately leading to the deterioration of bone and the 
onset of osteoporosis (Jones et al. 2002, Szollar et al. 1998). Further, it has been shown that the 
duration of paralysis (DoP) is related to the amount of post-SCI bone loss (Dionyssiotis et al. 
2011). Due to the loss of muscle activity below the level of injury and the mechanical, 
neurological, and hormonal changes accompanying SCI, the treatment of bone loss proves to be 
difficult and research for more effective means to salvage bone is imperative. This rapid decrease 
in bone density that manifests just days after SCI is reported to last between one to three years 
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(Garland et al. 1992, Sorensen et al. 1998, Shields 2002). One study observed the rate of bone 
loss to be 2-4% every month (Wilmet et al. 1995). Another study, following male adults less than 
40 years of age with SCI, reported a 33% loss in bone mass of the lower extremities within three 
to four months post injury, while other studies report as much as 50% loss in BMD within the 
first three years post injury (Garland et al. 1992, Eser et al. 2004, Sorensen et al. 1998). After the 
initial episode of rapid bone loss, demineralization decelerates: individuals eventually either 
reach a steady state or bone will continue to demineralize at a slower rate for several years 
(Shields 2002, Eser et al. 2004, Rittweger et al. 2006). Bone loss after SCI has been shown to 
vary between and within regions of the body. Not only do the sublesional and supralesional areas 
differ in bone metabolism, but also among different bone tissues such as cortical and trabecular 
(Jones et al. 2002). Specifically, rapid trabecular bone loss has been shown to level off after a 
few years post SCI while cortical bone has been shown to persist in slowly losing mass fore 
more than ten years (Giangregorio et al. 2006). Trabecular bone is synonymous with cancellous 
bone, and is abundant in the spine and both proximal and distal epiphysis and metaphysis of long 
bones. Trabecular bone is more susceptible to demineralization than cortical bone because the 
remodeling processes of these two types of osseous tissues are markedly distinct (Svircev 2007, 
Frost 1985). Due to the larger surface area of cancellous bone, more opportunities for metabolic 
processes are available than in more compact cortical bone surface (Hangartner et al. 1994); one 
study of bone loss in paraplegic individuals found that cancellous bone loss was twice as fast as 
cortical bone (Sorensen et al. 1998). In contrast, cortical bone that constitutes much of the 
diaphysis of long bones undergoes a considerably slower thinning process that gradually reduces 
overall bone strength (Frey-Rindova et al. 2000). The current study suggests that short-term 
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minocycline treatment may have a more pronounced effect on spongy trabecular, or cancellous, 
bone compared to cortical bone (Figures 6 and 7). Since the aforementioned studies exhibited 
evidence for a greater, more rapid loss in spongy bone than compact bone in the early phase of 
injury, minocycline bears potential as a therapeutic agent in alleviating post-SCI osteoporosis by 
bolstering the integrity of trabeculae. 
Significant differences in MS and BFR were observed between the minocycline-treated and 
vehicle-treated SCI groups. MS is a kinetic measure of the extent of bone surface actively 
mineralizing. BFR takes into account how much of the bone surface is actively mineralizing, 
which depends on the number of osteoblasts that are active; BFR multiples the average work of 
each osteoblast by the fraction of bone surface with active osteoblasts (MAR x MS/BS). MAR is 
the rate at which osteoblasts are making matrix, and since matrix calcifies at a constant rate, 
MAR measures the average activity of the osteoblasts in a section of bone being analyzed. The 
results of this study show that minocycline treatment increases the area of bone surface actively 
mineralizing and the overall rate of new bone formation. These outcomes hold promise, since 
evidence of enhanced mineralization means the organism may be able to counter the early 
deleterious effects of SCI on bone integrity. The extent of bone loss in individuals suffering with 
SCI is thought to be multifactorial, being influenced by the degree of injury, extent of injury 
(complete or incomplete), age, and length of time since injury (Jones et al. 2002, Maynard et al. 
1995). Given the age of our subjects (roughly three months), rescuing bone formation is 
clinically important. 
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In spite of the vehicle-treated SCI group having higher total BMD, which is a composite of 
cortical and cancellous measures, Figures 6 and 7 show that the vehicle-treated SCI subjects had 
higher cortical BMD but slightly lower cancellous BMD compared to the minocycline group. 
Cortical bone is compact, consisting of closely packed haversian systems; it is much denser, 
stronger, and stiffer than its cancellous counterpart. Cancellous bone is spongy, has a greater 
surface area, and is ideal for metabolic activity, such as exchange of calcium ions. Thus, even 
though the vehicle-treated SCI group displayed higher total BMD, it may be because the 
minocycline group had a larger percentage of bone undergoing mineralization in which the bone 
has not hardened yet, reducing the density measure. To confirm this notion, additional studies 
would be needed to follow the animals on a longer timeline. Another thing to consider is that, 
like most other tetracycline drugs, minocycline has been associated with metal ion chelation 
(Garrido-Mesa et al. 2013). It’s possible that minocycline chelates calcium ions and prevents 
them from being used to densify bones, thus contributing to the lower total BMD seen in Figure 
5. It’s also possible that calcium ion chelation is what enables minocycline to enhance 
mineralization, which may eventually contribute substantially to bone density if given enough 
time. Interestingly, Figures 5 and 7 show that the vehicle-treated SCI group has higher total 
BMD and cortical BMD compared to the intact group. This could mean that traumatic injury 
results in some type of compensation through bone calcification, or hardening of the bones. 
Consistent with this notion, is that intact controls had higher cancellous BMD than the vehicle-
treated SCI group in Figure 6. 
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In summary, administration of minocycline was able to significantly enhance active bone 
mineralization and overall new bone formation rates in a rodent SCI model compared to vehicle-
treated SCI controls. Due to the rapid and severe bone loss observed after SCI, a means to bolster 
bone quality in individuals suffering with SCI is urgent. The current study suggests that 
minocycline may be able to significantly remineralize bone after injury, however more 
exploration should be done in the context of drug-assisted bone remodeling for traumatic injury 
recovery. The results of this study are promising, but would be more reliable if the sample size 
per treatment group were increased. Studying older animals, where density is the primary 
outcome measure, may also provide insight into the drug’s effects in more mature populations. 
Additionally, following subjects for an elongated period of time may shed some light on the 
long-term effects of the augmented mineralization induced by minocycline to see whether it will 
eventually do significant work on cortical bone as well. Serum assessments could also be 
incorporated to track changes in various cytokines throughout the recovery period to see what 
correlation there may be between minocycline treatment and osteoclasteogenesis. To deepen the 
understanding of the effects of calcium ion chelation in post-SCI bone loss, an alternative 
treatment using a non-chelating tetracycline such as 12S-hydroxy-1,12-pyrazolinominocycline 
could be incorporated as a control group. With the data imparted from this study, minocycline 
continues to bear promise in the field of post-injury osteology. Even though it may not reduce 
bone resorption, it seems to be actively supporting new bone formation, which could be just as 
important in maintaining bone integrity. Due to the complexity of neurogenic osteoporosis, 
which describes bone deterioration after SCI (Weiss 2008), increased research is essential for the 
benefit of the spinally injured population.  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